Characteristics of antibody produced during chronic treatment with LHRH

G. M. Brown; G. R. Van Loon; B. C.W. Hummel; L. J. Grota; A. Arimura; A. V. Schally

doi:10.1210/jcem-44-4-784

Characteristics of antibody produced during chronic treatment with LHRH

G. M. Brown, G. R. Van Loon, B. C.W. Hummel, L. J. Grota, A. Arimura, A. V. Schally

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

In a patient with hypogonadotropic hypogonadism treated with luteinizing hormone releasing hormone (LHRH), secondary failure of both subjective and hormone responses occurred at the time of appearance of binding of ¹²⁵I LHRH by the patient's serum. On electrophoresis of the patient's serum with ¹²⁵I LHRH, label was found only in the gamma globulin region. ¹²⁵I LHRH added to the patient's serum was precipitated by sheep antihuman immunoglobulin G (anti IgG) but not by sheep anti human immunoglobulin M (anti IgM). Competitive displacement of ¹²⁵I LHRH by unlabeled LHRH was demonstrated while TSH releasing hormone (TRH), somatostatin and rat pituitary hormones showed no displacement when tested at concentrations 5 x 10⁶ greater than that of LHRH. Studies using 14 different analogs of LHRH revealed that those with changes at the carboxy terminus showed binding similar to LHRH. It is concluded that IgG antibody to LHRH was produced in this patient by repeated administration of synthetic LHRH. It is further concluded that antibody specificity is directed toward the N terminus region.

Original language	English (US)
Pages (from-to)	784-790
Number of pages	7
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	44
Issue number	4
DOIs	https://doi.org/10.1210/jcem-44-4-784
State	Published - Apr 1977
Externally published	Yes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1210/jcem-44-4-784

Fingerprint Dive into the research topics of 'Characteristics of antibody produced during chronic treatment with LHRH'. Together they form a unique fingerprint.

Cite this

@article{3a73827286b24260bf5298fc4451fcc0,

title = "Characteristics of antibody produced during chronic treatment with LHRH",

abstract = "In a patient with hypogonadotropic hypogonadism treated with luteinizing hormone releasing hormone (LHRH), secondary failure of both subjective and hormone responses occurred at the time of appearance of binding of 125I LHRH by the patient's serum. On electrophoresis of the patient's serum with 125I LHRH, label was found only in the gamma globulin region. 125I LHRH added to the patient's serum was precipitated by sheep antihuman immunoglobulin G (anti IgG) but not by sheep anti human immunoglobulin M (anti IgM). Competitive displacement of 125I LHRH by unlabeled LHRH was demonstrated while TSH releasing hormone (TRH), somatostatin and rat pituitary hormones showed no displacement when tested at concentrations 5 x 106 greater than that of LHRH. Studies using 14 different analogs of LHRH revealed that those with changes at the carboxy terminus showed binding similar to LHRH. It is concluded that IgG antibody to LHRH was produced in this patient by repeated administration of synthetic LHRH. It is further concluded that antibody specificity is directed toward the N terminus region.",

author = "Brown, {G. M.} and {Van Loon}, {G. R.} and Hummel, {B. C.W.} and Grota, {L. J.} and A. Arimura and Schally, {A. V.}",

year = "1977",

month = apr,

doi = "10.1210/jcem-44-4-784",

language = "English (US)",

volume = "44",

pages = "784--790",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "4",

}

TY - JOUR

T1 - Characteristics of antibody produced during chronic treatment with LHRH

AU - Brown, G. M.

AU - Van Loon, G. R.

AU - Hummel, B. C.W.

AU - Grota, L. J.

AU - Arimura, A.

AU - Schally, A. V.

PY - 1977/4

Y1 - 1977/4

N2 - In a patient with hypogonadotropic hypogonadism treated with luteinizing hormone releasing hormone (LHRH), secondary failure of both subjective and hormone responses occurred at the time of appearance of binding of 125I LHRH by the patient's serum. On electrophoresis of the patient's serum with 125I LHRH, label was found only in the gamma globulin region. 125I LHRH added to the patient's serum was precipitated by sheep antihuman immunoglobulin G (anti IgG) but not by sheep anti human immunoglobulin M (anti IgM). Competitive displacement of 125I LHRH by unlabeled LHRH was demonstrated while TSH releasing hormone (TRH), somatostatin and rat pituitary hormones showed no displacement when tested at concentrations 5 x 106 greater than that of LHRH. Studies using 14 different analogs of LHRH revealed that those with changes at the carboxy terminus showed binding similar to LHRH. It is concluded that IgG antibody to LHRH was produced in this patient by repeated administration of synthetic LHRH. It is further concluded that antibody specificity is directed toward the N terminus region.

AB - In a patient with hypogonadotropic hypogonadism treated with luteinizing hormone releasing hormone (LHRH), secondary failure of both subjective and hormone responses occurred at the time of appearance of binding of 125I LHRH by the patient's serum. On electrophoresis of the patient's serum with 125I LHRH, label was found only in the gamma globulin region. 125I LHRH added to the patient's serum was precipitated by sheep antihuman immunoglobulin G (anti IgG) but not by sheep anti human immunoglobulin M (anti IgM). Competitive displacement of 125I LHRH by unlabeled LHRH was demonstrated while TSH releasing hormone (TRH), somatostatin and rat pituitary hormones showed no displacement when tested at concentrations 5 x 106 greater than that of LHRH. Studies using 14 different analogs of LHRH revealed that those with changes at the carboxy terminus showed binding similar to LHRH. It is concluded that IgG antibody to LHRH was produced in this patient by repeated administration of synthetic LHRH. It is further concluded that antibody specificity is directed toward the N terminus region.

UR - http://www.scopus.com/inward/record.url?scp=0017618398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017618398&partnerID=8YFLogxK

U2 - 10.1210/jcem-44-4-784

DO - 10.1210/jcem-44-4-784

M3 - Article

C2 - 321467

AN - SCOPUS:0017618398

VL - 44

SP - 784

EP - 790

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -